I'm LongbridgeAI, I can summarize articles.Cryo Cell International reported Q3 FY2026 revenue of $7.82M, flat year-over-year. Growth in recurring storage fees was offset by a decline in new specimen enrollments. Operational expansion continues with a new Durham facility, but planned clinic and biopharma initiatives are paused due to a license dispute with Duke pending arbitration.
CRYO CELL INTERNATIONAL INC reported third-quarter fiscal 2026 revenue of $7.82M, essentially flat with $7.83M in the year-ago quarter, as modest growth in recurring storage fees was offset by fewer new specimen enrollments.
Financial Highlights
- Revenue: $7.82M for 3Q FY2026, compared with $7.83M in the year-ago quarter; YoY change 0%.
- Net income: (Not reported in Part I Items 1–2); omitted per instructions.
- Diluted EPS: (Not reported in Part I Items 1–2); omitted per instructions.
Business Highlights
- Total revenue roughly flat year-to-date at about $23.3M versus $23.7M prior-year, with recurring storage growth of roughly 3% offset by a 15–16% decline in new specimen processing.
- Channel and product mix: recurring storage fees provided modest growth while product and public bank sales were volatile but added incremental revenue.
- Operational capacity expanded with a 56,000 sq ft cold storage facility in Durham (ExtraVault) to support third-party biorepository and MSC lab services.
- Planned clinic, biopharma manufacturing and Celle spinoff initiatives are paused due to a license dispute with Duke; related investments are on hold pending arbitration.
- Company maintains cGMP/cGTP, AABB/FACT accreditations and reports 100% historical specimen viability on thaw along with its proprietary PrepaCyte®-CB processing claim.
Original SEC Filing: CRYO CELL INTERNATIONAL INC [ CCEL ] - 10-Q - Oct. 09, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.